Skip to main content
Clinical Trials/NCT05570929
NCT05570929
Recruiting
Not Applicable

Observation of Alterations in Kidney Function, Immune System and Gut Mircobiota After Living Donor Kidney Transplantation

Charite University, Berlin, Germany1 site in 1 country20 target enrollmentFebruary 7, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Kidney Diseases
Sponsor
Charite University, Berlin, Germany
Enrollment
20
Locations
1
Primary Endpoint
Fecal microbiome taxonomy (Shannon-Index)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a longitudinal observation of kidney function, immune system and gut microbiota before and 24 weeks after a live kidney transplantation conducted in donor and recipient pairs living in the same household. Outcome measures include kidney function, body composition, blood pressure, gut microbiome composition, metabolomics and immune cell states.

Registry
clinicaltrials.gov
Start Date
February 7, 2023
End Date
November 1, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Till Schütte

Principle Investigator

Charite University, Berlin, Germany

Eligibility Criteria

Inclusion Criteria

  • Body-Mass-Index 18,5 - 34,9 kg/m2
  • Planned living kidney donation / transplantation

Exclusion Criteria

  • Clinically relevant heart, lung, liver, and kidney diseases
  • Postoperative phase
  • Acute infections
  • Vegan diet
  • Change of body weight of more than 10% in the month prior to study entry
  • Known drug or alcohol abuse

Outcomes

Primary Outcomes

Fecal microbiome taxonomy (Shannon-Index)

Time Frame: Change from Baseline at 24 weeks

Measured by 16S amplicon sequencing

Secondary Outcomes

  • Fat free mass(Change from Baseline at 24 weeks)
  • Serum short-chain fatty acid concentration(Change from Baseline at 24 weeks)
  • Fecal short-chain fatty acid concentration(Change from Baseline at 24 weeks)
  • Office systolic blood pressure(Change from Baseline at 24 weeks)
  • Functional capacity of gut microbiota(Change from Baseline at 24 weeks)
  • Fecal tryptophan metabolites concentration(Change from Baseline at 24 weeks)
  • Body fat content(Change from Baseline at 24 weeks)
  • Frequency of circulating T-cell subtypes(Change from Baseline at 24 weeks)
  • Serum tryptophan metabolites concentration(Change from Baseline at 24 weeks)
  • Office diastolic blood pressure(Change from Baseline at 24 weeks)

Study Sites (1)

Loading locations...

Similar Trials